Skip to main content

Table 1 Patient characteristics a

From: Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative

Characteristics All (n= 65) Pso (n= 38) PsA (n= 27) P-value
Age, yr 53 (41 to 61) 54 (41 to 65) 52 (41 to 59) 0.526
Males, n (%) 35 (54) 21 (55) 14 (52) 0.806
Psoriasis disease duration, yr 20 (9 to 32) 20 (8 to 35) 20 (10 to 31) 0.931
Body surface area score, mean (SD) 9.2 (16) 8.1 (13.7) 10.8 (19.0) 0.827
PASI score, mean (SD) 7.8 (9.3) 7.3 (7.9) 8.7 (11.2) 0.967
Psoriatic arthritis, n (%) 27 (41)
Psoriatic arthritis disease duration, yr 10 (4 to 15.5)
Tender joint count (0 to 68), mean (SD) 8.9 (10.8)
Swollen joint count (0 to 66), mean (SD) 5.4 (9.0)
ASAS inflammatory back pain criteria met, n (%) 4 (17)
Calin inflammatory back pain criteria met, n (%) 5 (21)
Enthesitis score (0 to 6), mean (SD) 1.0 (1.5)
Dactylitis count (0 to 20), mean (SD) 1.4 (3.8)
Sacroiliac disease diagnosed by CT, n (%) 12 (44)
DMARD therapy, n (%) 6 (9) 2 (5) 4 (15) 0.224
Biologic therapy, n (%) 25 (39) 10 (26) 15 (56) 0.022
DMARD and biologic therapy, n (%) 4 (6) 2 (5) 2 (7) 1.000
NSAID therapy, n (%) 15 (23) 3 (8) 12 (44) 0.001
Phototherapy, n (%) 3 (5) 1 (3) 2 (7) 0.565
Topical steroid therapy, n (%) 24 (37) 14 (37) 10 (37) 1.000
Systemic steroid therapy, n (%) 1 (2) 0 (0) 1 (4) 0.415
Diabetes mellitus, n (%) 7 (11) 4 (11) 3 (11) 1.000
Hypertension, n (%) 21 (32) 13 (34) 8 (30) 0.791
Dyslipidemia, n (%) 44 (68) 29 (76) 15 (56) 0.108
Current tobacco use, n (%) 6 (9) 3 (8) 3 (11) 1.000
Former tobacco use, n (%) 18 (28) 12 (32) 6 (22) 0.684
Pack-years tobacco use 0 (0 to 4.5) 0 (0 to 5) 0 (0 to 0.8) 0.590
Diabetes mellitus therapy, n (%) 4 (6) 2 (5) 2 (7) 1.000
Antihypertensive therapy, n (%) 12 (19) 7 (18) 5 (19) 1.000
Hyperlipidemia therapy, n (%) 24 (37) 15 (39) 9 (33) 0.795
Body mass index, kg/m 2 29 (25.9 to 32.3) 29 (24.9 to 32.4) 29 (26.7 to 32) 0.572
Systolic blood pressure, mmHg 125 (116 to 135) 129 (120 to 135) 122 (115 to 133) 0.266
Diastolic blood pressure, mmHg 72 (65 to 78) 71 (66 to 78) 74 (63 to 79) 0.719
Fasting blood glucose, mg/dl 94 (89 to 104) 94 (89 to 104) 94 (89 to 107) 0.895
Total cholesterol, mg/dl 184 (158 to 203) 185 (158 to 207) 172 (157 to 201) 0.910
Triglycerides, mg/dl 108 (84 to 137) 109 (84 to 149) 101 (81 to 131) 0.604
High-density lipoprotein cholesterol, mg/dl 52 (42 to 63) 52 (42 to 69) 51 (47 to 59) 0.947
Low-density lipoprotein cholesterol, mg/dl 96 (80 to 125) 95 (80 to 125) 98 (78 to 125) 0.851
Erythrocyte sedimentation rate, mm/hr 8 (5 to 13) 8 (4 to 10) 12 (5 to 18) 0.097
High-sensitivity C-reactive protein, g/dl 1.7 (0.7 to 4.2) 1.2 (0.7 to 3.1) 3.0 (0.8 to 8) 0.221
  1. aASAS, Assessment of SpondyloArthritis international Society; DMARD, Disease-modifying antirheumatic drug; IQR, Interquartile range; NSAID, Nonsteroidal anti-inflammatory drug; PASI, Psoriasis Area and Severity Index; PsA, Psoriatic arthritis; Pso, Psoriasis. Data are reported as median (IQR) unless indicated otherwise. DMARD therapy denotes methotrexate use, except for 1 patient who was taking both methotrexate and hydroxychloroquine. Biologic therapy indicates active TNF antagonist or anti-IL-12/23 receptor use except for one patient who was treated with abatacept for psoriatic arthritis. Reported P-values are for comparisons of Pso vs. PsA using Fisher’s exact tests for categorical variables, Mann-Whitney U tests for non-normally distributed continuous variables, and Student’s t-tests for normally distributed continuous variables. P < 0.05 was set as the significance level.